Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG

Zoárd Tibor Krasznai, Ágnes Tóth, Pál Mikecz, Zoltán Fodor, Gábor Szabó, L. Galuska, Z. Hernádi, K. Goda

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

P-glycoprotein (Pgp, ABCB1) is one of the active efflux pumps that are able to extrude a large variety of chemotherapeutic drugs from the cells, causing the phenomenon of multidrug resistance. It has been shown earlier that the combined application of a class of Pgp modulators (e.g. cyclosporine A and SDZ PSC 833) used at low concentrations and UIC2 antibody is a novel, specific, and effective way of blocking Pgp function (Goda et al., 2007). In the present work we study the UIC2 antibody mediated Pgp inhibition in more detail measuring the accumulation of tumor diagnostic radiotracers, 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) and [99mTc]hexakis-2-methoxybutyl isonitrile (99mTc-MIBI), into Pgp+ (A2780AD) and Pgp- (A2780) human ovarian carcinoma cells.Co-incubation of cells with UIC2 and cyclosporine A (CSA, 2μM) increased the binding of UIC2 more than 3-fold and reverted the rhodamine 123 (R123), daunorubicin (DNR) and 99mTc-MIBI accumulation of the Pgp+ 2780AD cells to approx. the same level as observed in Pgp- cells. Similarly, 50μM paclitaxel (Pacl) increased UIC2 binding, and consequently reinstated the uptake of R123, DNR and 99mTc-MIBI into the Pgp+ cells. Blocking Pgp by combined treatments with CSA+UIC2 or Pacl+UIC2 also decreased the glucose metabolic rate of the A2780AD Pgp+ cells measured in 18FDG accumulation experiments suggesting that the maintenance of Pgp activity requires a considerable amount of energy. Similar treatments of the A2780 Pgp- cells did not result in significant change in the R123, DNR, 99mTc-MIBI and 18FDG accumulation demonstrating that the above effects are Pgp-specific. Thus, combined treatment with the UIC2 antibody and Pgp modulators can completely block the function of Pgp in human ovarian carcinoma cells and this effect can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.

Original languageEnglish
Pages (from-to)665-669
Number of pages5
JournalEuropean Journal of Pharmaceutical Sciences
Volume41
Issue number5
DOIs
Publication statusPublished - Dec 23 2010

Fingerprint

Glucose
Antibodies
Rhodamine 123
Neoplasms
Daunorubicin
Paclitaxel
Cyclosporine
Carcinoma
In Vitro Techniques
Multiple Drug Resistance
P-Glycoprotein
Maintenance
Pharmaceutical Preparations

Keywords

  • FDG
  • Tc-MIBI
  • Multidrug resistance
  • P-glycoprotein
  • UIC2 monoclonal antibody

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG. / Krasznai, Zoárd Tibor; Tóth, Ágnes; Mikecz, Pál; Fodor, Zoltán; Szabó, Gábor; Galuska, L.; Hernádi, Z.; Goda, K.

In: European Journal of Pharmaceutical Sciences, Vol. 41, No. 5, 23.12.2010, p. 665-669.

Research output: Contribution to journalArticle

@article{a961cc87df91481caf2a8aa5ea96405f,
title = "Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG",
abstract = "P-glycoprotein (Pgp, ABCB1) is one of the active efflux pumps that are able to extrude a large variety of chemotherapeutic drugs from the cells, causing the phenomenon of multidrug resistance. It has been shown earlier that the combined application of a class of Pgp modulators (e.g. cyclosporine A and SDZ PSC 833) used at low concentrations and UIC2 antibody is a novel, specific, and effective way of blocking Pgp function (Goda et al., 2007). In the present work we study the UIC2 antibody mediated Pgp inhibition in more detail measuring the accumulation of tumor diagnostic radiotracers, 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) and [99mTc]hexakis-2-methoxybutyl isonitrile (99mTc-MIBI), into Pgp+ (A2780AD) and Pgp- (A2780) human ovarian carcinoma cells.Co-incubation of cells with UIC2 and cyclosporine A (CSA, 2μM) increased the binding of UIC2 more than 3-fold and reverted the rhodamine 123 (R123), daunorubicin (DNR) and 99mTc-MIBI accumulation of the Pgp+ 2780AD cells to approx. the same level as observed in Pgp- cells. Similarly, 50μM paclitaxel (Pacl) increased UIC2 binding, and consequently reinstated the uptake of R123, DNR and 99mTc-MIBI into the Pgp+ cells. Blocking Pgp by combined treatments with CSA+UIC2 or Pacl+UIC2 also decreased the glucose metabolic rate of the A2780AD Pgp+ cells measured in 18FDG accumulation experiments suggesting that the maintenance of Pgp activity requires a considerable amount of energy. Similar treatments of the A2780 Pgp- cells did not result in significant change in the R123, DNR, 99mTc-MIBI and 18FDG accumulation demonstrating that the above effects are Pgp-specific. Thus, combined treatment with the UIC2 antibody and Pgp modulators can completely block the function of Pgp in human ovarian carcinoma cells and this effect can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.",
keywords = "FDG, Tc-MIBI, Multidrug resistance, P-glycoprotein, UIC2 monoclonal antibody",
author = "Krasznai, {Zo{\'a}rd Tibor} and {\'A}gnes T{\'o}th and P{\'a}l Mikecz and Zolt{\'a}n Fodor and G{\'a}bor Szab{\'o} and L. Galuska and Z. Hern{\'a}di and K. Goda",
year = "2010",
month = "12",
day = "23",
doi = "10.1016/j.ejps.2010.09.009",
language = "English",
volume = "41",
pages = "665--669",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG

AU - Krasznai, Zoárd Tibor

AU - Tóth, Ágnes

AU - Mikecz, Pál

AU - Fodor, Zoltán

AU - Szabó, Gábor

AU - Galuska, L.

AU - Hernádi, Z.

AU - Goda, K.

PY - 2010/12/23

Y1 - 2010/12/23

N2 - P-glycoprotein (Pgp, ABCB1) is one of the active efflux pumps that are able to extrude a large variety of chemotherapeutic drugs from the cells, causing the phenomenon of multidrug resistance. It has been shown earlier that the combined application of a class of Pgp modulators (e.g. cyclosporine A and SDZ PSC 833) used at low concentrations and UIC2 antibody is a novel, specific, and effective way of blocking Pgp function (Goda et al., 2007). In the present work we study the UIC2 antibody mediated Pgp inhibition in more detail measuring the accumulation of tumor diagnostic radiotracers, 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) and [99mTc]hexakis-2-methoxybutyl isonitrile (99mTc-MIBI), into Pgp+ (A2780AD) and Pgp- (A2780) human ovarian carcinoma cells.Co-incubation of cells with UIC2 and cyclosporine A (CSA, 2μM) increased the binding of UIC2 more than 3-fold and reverted the rhodamine 123 (R123), daunorubicin (DNR) and 99mTc-MIBI accumulation of the Pgp+ 2780AD cells to approx. the same level as observed in Pgp- cells. Similarly, 50μM paclitaxel (Pacl) increased UIC2 binding, and consequently reinstated the uptake of R123, DNR and 99mTc-MIBI into the Pgp+ cells. Blocking Pgp by combined treatments with CSA+UIC2 or Pacl+UIC2 also decreased the glucose metabolic rate of the A2780AD Pgp+ cells measured in 18FDG accumulation experiments suggesting that the maintenance of Pgp activity requires a considerable amount of energy. Similar treatments of the A2780 Pgp- cells did not result in significant change in the R123, DNR, 99mTc-MIBI and 18FDG accumulation demonstrating that the above effects are Pgp-specific. Thus, combined treatment with the UIC2 antibody and Pgp modulators can completely block the function of Pgp in human ovarian carcinoma cells and this effect can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.

AB - P-glycoprotein (Pgp, ABCB1) is one of the active efflux pumps that are able to extrude a large variety of chemotherapeutic drugs from the cells, causing the phenomenon of multidrug resistance. It has been shown earlier that the combined application of a class of Pgp modulators (e.g. cyclosporine A and SDZ PSC 833) used at low concentrations and UIC2 antibody is a novel, specific, and effective way of blocking Pgp function (Goda et al., 2007). In the present work we study the UIC2 antibody mediated Pgp inhibition in more detail measuring the accumulation of tumor diagnostic radiotracers, 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) and [99mTc]hexakis-2-methoxybutyl isonitrile (99mTc-MIBI), into Pgp+ (A2780AD) and Pgp- (A2780) human ovarian carcinoma cells.Co-incubation of cells with UIC2 and cyclosporine A (CSA, 2μM) increased the binding of UIC2 more than 3-fold and reverted the rhodamine 123 (R123), daunorubicin (DNR) and 99mTc-MIBI accumulation of the Pgp+ 2780AD cells to approx. the same level as observed in Pgp- cells. Similarly, 50μM paclitaxel (Pacl) increased UIC2 binding, and consequently reinstated the uptake of R123, DNR and 99mTc-MIBI into the Pgp+ cells. Blocking Pgp by combined treatments with CSA+UIC2 or Pacl+UIC2 also decreased the glucose metabolic rate of the A2780AD Pgp+ cells measured in 18FDG accumulation experiments suggesting that the maintenance of Pgp activity requires a considerable amount of energy. Similar treatments of the A2780 Pgp- cells did not result in significant change in the R123, DNR, 99mTc-MIBI and 18FDG accumulation demonstrating that the above effects are Pgp-specific. Thus, combined treatment with the UIC2 antibody and Pgp modulators can completely block the function of Pgp in human ovarian carcinoma cells and this effect can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.

KW - FDG

KW - Tc-MIBI

KW - Multidrug resistance

KW - P-glycoprotein

KW - UIC2 monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=78349307009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349307009&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2010.09.009

DO - 10.1016/j.ejps.2010.09.009

M3 - Article

VL - 41

SP - 665

EP - 669

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

IS - 5

ER -